Found: 15
Select item for more details and to access through your institution.
CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection.
- Published in:
- Molecular Medicine, 2012, v. 18, n. 10, p. 1240, doi. 10.2119/molmed.2012.00206
- By:
- Publication type:
- Article
CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection.
- Published in:
- Molecular Medicine, 2012, v. 18, n. 8, p. 1240, doi. 10.2119/molmed.2012.00206
- By:
- Publication type:
- Article
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1400553
- By:
- Publication type:
- Article
Pharmacology Lessons From Chemoprophylaxis Studies.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. suppl_1, p. S52, doi. 10.1093/cid/ciu250
- By:
- Publication type:
- Article
New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2014, v. 69, n. 7, p. 1911, doi. 10.1093/jac/dku060
- By:
- Publication type:
- Article
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2011, v. 66, n. 4, p. 885, doi. 10.1093/jac/dkq546
- By:
- Publication type:
- Article
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous Cells after Vaccination of HIV Infected Individuals.
- Published in:
- PLoS ONE, 2013, v. 8, n. 10, p. 1, doi. 10.1371/journal.pone.0074389
- By:
- Publication type:
- Article
A Randomised, Placebo-Controlled, First-In-Human Study of a Novel Clade C Therapeutic Peptide Vaccine Administered <i>Ex Vivo</i> to Autologous White Blood Cells in HIV Infected Individuals.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0073765
- By:
- Publication type:
- Article
Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients.
- Published in:
- Drugs in R&D, 2015, v. 15, n. 1, p. 141, doi. 10.1007/s40268-015-0087-7
- By:
- Publication type:
- Article
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
- Published in:
- 2016
- By:
- Publication type:
- journal article
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).
- Published in:
- 2016
- By:
- Publication type:
- journal article